Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications
BCL11B targeting in tumor CD8 + T cells amplifies anti-tumor response by blocking exhaustion while promoting stemness and cytotoxicity.
Journal: bioRxiv : the preprint server for biology
Published: August 15, 2026
Controlling treatment toxicity in ovarian cancer to prime the patient for tumor extinction therapy.
Journal: bioRxiv : the preprint server for biology
Published: August 12, 2025
Training, Validating, and Testing Machine Learning Prediction Models for Endometrial Cancer Recurrence.
Journal: JCO precision oncology
Published: May 05, 2025
Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR.
Journal: Research square
Published: February 27, 2024
CAR-T Cell Therapy in Ovarian Cancer: Where Are We Now?
Journal: Diagnostics (Basel, Switzerland)
Published: February 12, 2024
Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR.
Journal: Nature communications
Published: February 07, 2024
Combination DNA Damage Response (DDR) Inhibitors to Overcome Drug Resistance in Ovarian Cancer.
Journal: Cancer treatment and research
Published: November 17, 2023
Dual blockade of BRD4 and ATR/WEE1 pathways exploits ARID1A loss in clear cell ovarian cancer.
Journal: Research square
Published: October 16, 2023
Controversies in the Staging of Patients with Locally Advanced Cervical Cancer.
Journal: Diagnostics (Basel, Switzerland)
Published: March 01, 2023
Humanized Patient-Derived Xenograft Models of Ovarian Cancer.
Journal: Methods in molecular biology (Clifton, N.J.)
Published: December 17, 2021
CCNE1 copy number is a biomarker for response to combination WEE1-ATR inhibition in ovarian and endometrial cancer models.
Journal: Cell reports. Medicine
Published: February 08, 2021
Last Updated: 09/26/2026